SEARCH

SEARCH BY CITATION

References

  • 1
    Bilardo CM, Wolf H, Stigter RH, Ville Y, Baez E, Visser GH, et al. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol 2004;23:11925.
  • 2
    Petersen SG, Wong SF, Urs P, Gray PH, Gardener GJ. Early onset, severe fetal growth restriction with absent or reversed end-diastolic flow velocity waveform in the umbilical artery: perinatal and long-term outcomes. Aust NZ J Obstet Gynaecol 2009;49:4551.
  • 3
    Wareing M, Myers JE, O’Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005;90:25505.
  • 4
    Lessoway VA, Schulzer M, Wittmann BK, Gagnon FA, Wilson RD. Ultrasound fetal biometry charts for a North American Caucasian population. J Clin Ultrasound 1998;26:43353.
  • 5
    von DadelszenP, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, et al. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Crit Care Med 2002;30:188392.
  • 6
    Gulmezoglu AM, Hofmeyr GJ. Calcium channel blockers for potential impaired fetal growth. Cochrane Database Syst Rev 2000;2:CD000049.
  • 7
    Winer N, Branger B, Azria E, Tsatsaris V, Philippe HJ, Roze JC, et al. L-Arginine treatment for severe vascular fetal intrauterine growth restriction: a randomized double-bind controlled trial. Clin Nutr 2009;28:2438.
  • 8
    Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:36982.